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Antenatal Corticosteroids in Preterm Small-for-Gestational Age Infants: A Systematic 1 
Review and Meta-Analysis 2 
Condensation 3 
 4 
Antenatal corticosteroids reduce neonatal mortality in SGA infants delivered preterm, with no 5 
apparent effect on neonatal morbidity.  6 
 7 
Short title:  SGA Infants and Steroids Systematic Review 8 
 9 
AJOG at a Glance 10 
A. Why was the study conducted? 11 
Prior literature offers conflicting evidence guiding antenatal corticosteroid (ACS) 12 
administration in small-for-gestational age (SGA) infants given their increased endogenous 13 
steroid exposure due to pathologic intrauterine stress. The present study estimates the effect 14 
of ACS on neonatal mortality and morbidity in preterm SGA infants through a systematic 15 
literature review and meta-analysis. 16 
 17 
B. What are the key findings? 18 
ACS administration in preterm SGA infants significantly reduces neonatal mortality, with no 19 
apparent effect on neonatal morbidity. 20 
 21 
C. What does the study add to what is already known? 22 
The SGA population is one of clinical interest that has not been a population of focus in 23 
large-scale randomized trials evaluating ACS administration and neonatal outcomes. Our 24 
focused analysis on ACS administration in SGA infants provides the highest level of 25 
evidence currently available demonstrating benefit of ACS administration for reducing 26 
neonatal mortality in SGA infants delivered preterm. 27 
 28 
 29 
Keywords: small-for-gestational age, fetal growth restriction, antenatal corticosteroids, neonatal 30 
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ABSTRACT  35 
Objective: To estimate the effect of antenatal corticosteroid (ACS) administration on neonatal 36 
mortality and morbidity in preterm small-for-gestational age (SGA) infants through a systematic 37 
review and meta-analysis. 38 
Data sources: A predefined, systematic search was conducted through Ovid Medline, Embase, 39 
Scopus, Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of 40 
Controlled Trials, World Health Organization International Clinical Trial Registry Portal, and 41 
ClinicalTrials.gov yielding 5,324 articles from 1970-2019.  42 
Study eligibility criteria:  Eligible studies compared neonatal morbidity and/or mortality among 43 
SGA infants delivered preterm who received ACS to those who did not.  44 
Study appraisal and synthesis methods: The primary outcome was neonatal mortality. 45 
Secondary outcomes were respiratory distress syndrome (RDS), necrotizing enterocolitis (NEC), 46 
intraventricular hemorrhage and/or periventricular leukomalacia (IVH and/or PVL), 47 
bronchopulmonary dysplasia or chronic lung disease of prematurity (BPD or CLD), or neonatal 48 
sepsis. We assessed heterogeneity via Higgins I2 and Cochrane’s Q test, and calculated pooled 49 
odds ratios (OR) with 95% confidence intervals (CI) using random effects models. 50 
Results: Sixteen observational cohort and case-control studies published from 1995-2018 met 51 
selection criteria for the systematic review and included 8,989 preterm SGA infants. ACS 52 
administration was explicitly reported among 8,376 SGA infants; 4,631 (55.3%) received ACS 53 
and 3,741 (44.7%) did not. Thirteen studies including 6,387 preterm SGA infants were then 54 
included in the meta-analysis. Neonatal mortality was significantly lower among infants who 55 
received ACS compared to those who did not (12 studies: 12.8% vs. 15.1%, pooled odds ratio 56 
[OR] 0.63 [95% CI 0.46-0.86]), with significant heterogeneity between studies (I2=55.1%, 57 
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p=0.011). There was no significant difference in RDS (12 studies: OR 0.89 [95% CI 0.69-1.15]), 58 
NEC (7 studies: OR 0.93 [95% CI 0.70-1.22]), IVH and/or PVL (10 studies: OR 0.82 [95% CI 59 
0.56-1.20]), BPD or CLD (8 studies: OR 1.11 [95% CI 0.88-1.41]), or neonatal sepsis (6 studies: 60 
OR 1.13 [95% CI 0.86-1.49]). 61 
Conclusions: These data show that ACS reduces neonatal mortality in SGA infants delivered 62 
preterm, with no apparent effect on neonatal morbidity. This supports the use of ACS to reduce 63 
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MANUSCRIPT BODY 95 
 96 
Introduction  97 
 98 
Small-for-gestational age (SGA) is commonly defined as birthweight less than the tenth 99 
percentile. SGA infants can be either constitutionally small or pathologically growth-restricted 100 
antenatally.1-2 Clinically, it can be difficult to differentiate the etiology of FGR (fetal growth 101 
restriction). Approximately 3 to 7% of newborns are affected by pathologic FGR, a major risk 102 
factor for preterm birth, and the incidence of FGR increases with increasing prematurity.3-5 FGR 103 
in a preterm neonate specifically carries an increased risk of perinatal morbidity and mortality.5,6   104 
Administration of antenatal corticosteroids (ACS) has become the standard of care in the 105 
setting of anticipated preterm delivery in order to prevent neonatal morbidity and mortality. ACS 106 
has been shown to reduce neonatal mortality by 31% in appropriate-for-gestational age (AGA) 107 
infants, with efficacy demonstrated specifically in reducing rates of respiratory distress 108 
syndrome, intraventricular hemorrhage and necrotizing enterocolitis, among other neonatal 109 
outcomes.7-9 However, large-scale prospective studies evaluating the effect of ACS on preterm 110 
birth outcomes have not made small-for-gestational age (SGA) infants a primary population of 111 
focus, with data for this population limited to mostly retrospective studies. Furthermore, clinical 112 
management related to ACS administration in pregnancies with SGA infants has wide variation 113 
largely guided by expert opinion without an evidence-based consensus.  114 
Due to pathologic intrauterine stress, SGA infants may be exposed to higher levels of 115 
endogenous corticosteroids at baseline as a result of multiple mechanisms. These mechanisms 116 
include increased fetal adrenal cortisol production, compromised ability to remove 117 
corticosteroids through the blood brain barrier or placenta, and reduced ability to block the 118 
passage of maternal cortisol across the placenta.10-18 As SGA infants are already exposed to 119 
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higher levels of endogenous steroids, the additional administration of exogenous ACS prior to 120 
impending preterm delivery may not offer additional benefit. In fact, exposure to single or 121 
repeated courses of corticosteroids in utero has been associated with reduced fetal growth; 122 
impaired cardiovascular and brain development; and impaired gas exchange and physiologic 123 
adaptive mechanisms in the growth-restricted neonate.10-18 Administration of exogenous ACS 124 
may ultimately alter the ability of an SGA infant to compensate for intrauterine stress caused by 125 
placental insufficiency.18 As a result, some researchers have postulated that administration of 126 
exogenous steroids may even be detrimental to SGA infants.2 127 
 128 
Objective 129 
Given limited and conflicting evidence guiding the use of ACS in SGA infants, the 130 
present study aims to summarize the totality of evidence on ACS administration in SGA infants 131 
at risk for preterm delivery. We performed a systematic literature review and meta-analysis to 132 
estimate the effect of ACS on neonatal mortality and morbidity in preterm SGA infants. We 133 
hypothesized that administration of ACS in preterm SGA infants would have limited benefit 134 





We used a predesigned methodology according to guidelines for Preferred Reporting 140 
Items for Systematic reviews and Meta-Analyses (PRISMA) and Meta-analyses of Observational 141 
Studies in Epidemiology (MOOSE).19,20 The study protocol was registered with PROSPERO 142 
(#156264).  143 
 144 
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Information Sources and Search Strategy 145 
A medical librarian searched published literature for records discussing ACS (i.e. 146 
betamethasone, dexamethasone, alternate drug names and suggested synonyms for 147 
dexamethasone and betamethasone), and preterm SGA infants. The librarian created search 148 
strategies using a combination of keywords and controlled vocabulary in Ovid Medline (1946-149 
present), Embase.com (1947-present), Scopus (1823-present), Cochrane Database of Systematic 150 
Reviews (CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), World Health 151 
Organization International Clinical Trial Registry Portal (WHO ICTRP), and Clinicaltrials.gov 152 
(1997-present). Animals were excluded using the OVID human filter recommended in Cochrane 153 
Handbook for Systematic Reviews of Interventions.21 The filter was translated to exclude animals 154 
in Embase and Scopus. All search strategies were completed initially in June 2019, and a total of 155 
10,139 results were exported to EndNote. 5,204 records were deleted after using the de-156 
duplication processes described by Bramer et al.22 A total of 4,935 unique records remained in 157 
the project library. In addition to these, 35 records were identified in ClinicalTrials.gov, and 24 158 
in World Health Organization International Clinical Trials Registry Portal (WHO ICTRP). A 159 
manual search of bibliographies of relevant articles was also performed.  160 
The search was updated in all databases again in May 2020. A total of 10,151 search 161 
results were exported from the databases without any date limits and were added to the project 162 
Endnote project library (15086). A total of 9,824 duplicates were removed and deleted revealing 163 
330 new citations. Due to the search and site no longer being available, the World Health 164 
Organization International Clinical Trials Registry Portal (WHO ICTRP) was not searched in 165 
May 2020. All references were exported to an excel workbook for review. Fully reproducible 166 
search strategies for each database can be found in the appendix. 167 
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Eligibility Criteria and Study Selection 168 
Two investigators (SAB and KEB) independently screened abstracts and articles 169 
pertaining to ACS administration that reported on neonatal mortality and/or other perinatal 170 
outcomes that contribute to overall neonatal morbidity or mortality in SGA infants, and extracted 171 
data from each study. Study corresponding authors were contacted via email in attempt to obtain 172 
missing data for outcomes of interest. Discrepancies in coding required agreement between 173 
authors (SAB, KEB and MT) to be considered resolved.  174 
Studies were included if they reported on SGA infants delivered preterm that received 175 
ACS, either betamethasone or dexamethasone, prior to delivery. Included studies reported on 176 
neonatal mortality and/or any of the following adverse perinatal outcomes: respiratory distress 177 
syndrome (RDS), bronchopulmonary dysplasia (BPD) or chronic lung disease of prematurity 178 
(CLD), necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH) and/or 179 
periventricular leukomalacia (PVL), or neonatal sepsis after delivery.  180 
Studies were excluded if they were a review article; included non-human, animal fetuses; 181 
did not report on outcomes distinctly for SGA infants according to ACS administration; analyzed 182 
combined effect of surfactant and steroids on perinatal outcomes or compared steroids to an 183 
alternative intervention; reported on the effect of repeated or “rescue” doses of steroids; included 184 
duplicate data previously reported in another publication by the same author; or included 185 
multiple gestations. Additionally, studies were excluded from the meta-analysis if they did not 186 
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Data Extraction 191 
The primary outcome was neonatal mortality. Secondary outcomes of interest were RDS, 192 
BPD or CLD, IVH and/or PVL, NEC and neonatal sepsis, as defined in Supplementary Table 1. 193 
Long term childhood neurodevelopmental outcomes were also extracted when available.  194 
For each study, when data were available, we extracted mean maternal age, maternal 195 
parity, mean gestational age at delivery, mean birth weight, number of infants delivered via 196 
Cesarean section, infant sex, number of infants who received surfactant, number of infants 197 
affected by chorioamnionitis, and use of surfactant or mechanical ventilation postnatally. 198 
Maternal risk factors and co-morbidities were also extracted, including gestational or pre-199 
gestational diabetes mellitus and maternal hypertensive disorders (chronic hypertension, 200 
pregnancy-induced hypertension, pre-eclampsia, eclampsia or HELLP syndrome). Each of the 201 
aforementioned variables was stratified by the number of SGA infants who did or did not receive 202 
ACS.   203 
 204 
Data Synthesis 205 
Meta-analysis was performed using the metan add-on program in Stata (Stata 2015 206 
Release 12, StataCorp, Texas, USA).  Two-by-two contingency tables were created to compare 207 
the presence or absence of neonatal mortality or adverse neonatal outcome stratified by ACS 208 
administration. Although the majority of studies were cohort studies, we calculated pooled odds 209 
ratios (OR) as one case control study was included. Random effects models were used to account 210 
for clinical heterogeneity between studies even when statistical heterogeneity was not evident. 211 
To further account for heterogeneity related to varied time periods among included studies, we 212 
also performed a subgroup analysis for neonatal mortality among studies that evaluated patients 213 
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up to the year 2010 analyzed separately from those that evaluated patients beyond the year 2010. 214 
Forest plots were created to visually assess both effect size and identify outliers.  215 
We estimated heterogeneity across studies and tested its significance using the Higgins I2 216 
statistic and Cochrane’s Q test. I2 of 50% was considered evidence of significant heterogeneity. 217 
Publication bias was evaluated visually using funnel plots and asymmetry was tested statistically 218 
using Egger’s test. 219 
 220 
Assessment of Risk of Bias 221 
Quality assessment to determine risk of bias of included studies was also performed using 222 
the Downs and Black assessment tool.23 The checklist is composed of 27 questions, with a total 223 
possible score of 28 for randomized and 25 for non-randomized studies. Downs and Black score 224 
ranges are given corresponding quality levels: excellent (26–28); good (20–25); fair (15–19); and 225 
poor (≤14). Only randomized studies can achieve a quality level of excellent according to the 226 
scoring methodology of the Downs and Black checklist. As all studies were observational and 227 




Study Selection 232 
 The search yielded 5,324 articles published from 1970-2019. Sixteen observational 233 
cohort and case-control studies published from 1995-2018 met inclusion and exclusion criteria 234 
and were selected for the systematic review. 24-39 In aggregate, the 16 studies included in the 235 
systematic review included 8,989 preterm SGA infants.  236 




Study Characteristics 238 
 All studies were observational, with fourteen retrospective cohort studies, one 239 
prospective cohort study, and one case-control study included (Table 1). ACS administration was 240 
explicitly reported among 8,376 SGA infants; 4,631 (55.3%) received ACS and 3,741 (44.7%) 241 
did not. Nine studies reported on type of ACS administered, with betamethasone the most 242 
commonly used in 8 studies; two studies included infants who received either betamethasone or 243 
dexamethasone. Ten studies specified birth weight less than the tenth percentile in their 244 
definition for SGA. Additional maternal and neonatal characteristics in the included studies are 245 
detailed in Tables 2 and 3, respectively.   246 
Table 4 contains weighted-averages for the primary and all secondary outcomes among 247 
SGA infants stratified by ACS administration. Fourteen studies reported on overall neonatal 248 
mortality, 14 studies reported on RDS, 8 studies reported on BPD or CLD, 7 studies reported on 249 
NEC and 6 studies reported on neonatal sepsis. Among 11 studies that reported on IVH and/or 250 
PVL, seven studies reported on IVH alone; 4 studies included grade 3 or 4 IVH and/or PVL as a 251 
combined outcome.26,32,37,38 252 
 Long-term neurodevelopmental outcomes were reported among three studies.30,31,35 Two 253 
studies reported on severe global delay up to three years of age as determined by a development 254 
quotient (DQ) less than 70, or more than two standard deviations below the mean DQ of 100, as 255 
defined by the Kyoto Scale of Psychological Development test or the Griffiths test for mental 256 
developmental scales.40,41 Among infants with long term follow up data, 16.8% (54/321) of 257 
infants that received ACS had severe global delay, while 13.5% (71/525) infants that did not 258 
receive ACS had severe global delay. Schaap et al. reported abnormal behavior in long-term 259 
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follow-up at school age of surviving infants, with 43% (21/62) of children who received ACS 260 
and 45% (19/45) of children who did not receive ACS exhibiting abnormal behavior.34 H wever, 261 
this study did not report how it classified abnormal behavior. 262 
 263 
Meta-analysis and Synthesis of Results 264 
Three studies did not provide raw data for neonatal outcomes according to ACS 265 
administration and thus were unable to be included in the meta-analysis. Among these three 266 
studies, Griffin et al. reported odds ratios for neonatal mortality; Bernstein et al. reported odds 267 
ratios for RDS; and Ley et al. reported odds ratios for neonatal mortality, RDS and IVH and/or 268 
PVL (Table 4).29,36,38 The remaining thirteen studies reported raw data for neonatal outcomes 269 
among 6,387 preterm SGA infants and were quantitatively synthesized in the meta-analysis. 24-270 
28,30-35,37,39 271 
ACS administration was associated with a significant reduction in neonatal mortality (12 272 
studies: 12.8% vs. 15.1%, OR 0.63 [95% confidence interval (CI) 0.46-0.86]). There was 273 
significant heterogeneity between studies (I2=55.1% [p=0.011]) (Figure 2). There was no 274 
evidence of publication bias (Figure 3, Egger’s p=0.87). In the subgroup analysis by study year, 275 
no significant difference in mortality was detected among studies that followed patients up to 276 
2010 (OR 0.93 [95% CI 0.71, 1.21], I2=0.0% [p=0.452], 7 studies), but a significant reduction in 277 
mortality was found among infants who received ACS among studies that followed patients after 278 
2010 (OR 0.48 [95% CI 0.38, 0.60], I2=5.0% [p=0.378]; 5 studies, Figure 4).  279 
Among the secondary outcomes, there was no significant difference in RDS (12 studies: 280 
OR 0.89 [95% CI 0.69-1.15], I2=66.7% [p=0.001], Supplementary Figure 1), NEC (7 studies: 281 
OR 0.93 [95% CI 0.70-1.22], I2=0.0% [p=0.447], Supplementary Figure 2), or IVH and/or PVL 282 
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(10 studies: OR 0.82 [95% CI 0.56-1.20], I2=53.1% [p=0.024], Supplementary Figure 3). Among 283 
the 3 studies that reported on individual values for IVH and PVL, only the values for IVH were 284 
included in the forest plot for IVH and/or PVL as IVH was more common in these studies.30-32 285 
Significant heterogeneity was seen in studies reporting RDS and IVH and/or PVL, as reflected 286 
by the I2 statistic. There was no significant difference in risk of BPD or CLD (8 studies: OR 1.11 287 
[95% CI 0.88-1.41], I2=40.2% [p=0.111], Supplementary Figure 4) and neonatal sepsis (6 288 
studies: OR 1.13 [95% CI 0.86-1.49], I2=0.0% [p=0.583], Supplementary Figure 5).  289 
 290 
Risk of Bias of Included Studies 291 
 In the quality assessment of included studies, the majority of studies were assessed to be 292 
“fair” quality, with two studies determined to be of “good” quality and two studies of “poor” 293 
quality (Table 5). Only two studies performed a power calculation and external validity was 294 
unable to be determined in most studies. While lack of randomization decreased the quality of all 295 
included studies, all studies achieved at least average (e.g. score of 3 or higher) internal validity 296 
in both the bias and confounding assessments by using appropriate statistical regression to adjust 297 




Main Findings and Comparison with with Existing Literature 302 
 303 
We found that ACS reduces neonatal mortality in SGA infants delivered preterm, with no 304 
apparent effect on individual neonatal morbidities. Our results are similar to those of a 2016 305 
systematic review and meta-analysis of 2,846 SGA infants in eight studies conducted up until 306 
2010 that found that administration of ACS to growth-restricted preterm infants did not improve 307 
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neonatal morbidity.42 However, in contrast to our findings, the 2016 meta-analysis was unable to 308 
detect a reduction in neonatal mortality with ACS. Our meta-analysis includes five studies with 309 
2,982 SGA infants (46.7% of the study population included in the meta-analysis) followed after 310 
2010, 2,124 (71.2%) of whom received ACS. Our meta-analysis provides a more current and 311 
comprehensive update to prior available data and supports ACS administration to SGA infants to 312 
reduce neonatal mortality. 313 
Of note, studies in our analysis that followed patients beyond 2010 include data 314 
predominately from the 2000s to 2010s, whereas studies that followed patients up to 2010 315 
included patient data also from the 1980s and 1990s. Multiple aspects of medical care and 316 
technology have evolved over the past few decades in an effort to reduce infant mortality with 317 
improved antenatal interventions, neonatal resuscitation, and other postnatal management among 318 
preterm infants. While our subgroup analysis seeks to account for these differences according to 319 
study period, it is plausible the reduction in mortality seen in studies that followed patients 320 
beyond 2010 could be attributed to other advancements in medical care for SGA infants 321 
delivered preterm, not solely due to ACS administration.  322 
 323 
Strengths and Limitations 324 
Our study offers several strengths. We included a large representative sample of 8,989 325 
preterm SGA infants, most with birthweight less than the tenth percentile. We used a predefined 326 
protocol and comprehensive search strategy to limit selection bias. The SGA population as the 327 
specific target in our analysis represents a major strength of our study as SGA infants, albeit an 328 
important population of clinical interest, have been either excluded from prior large-scale trials 329 
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evaluating ACS administration and neonatal outcomes or not specifically a population of focused 330 
analysis in these trials.  331 
As with all meta-analyses, the limitations of the primary studies must be considered. 332 
Eleven of the thirteen included studies included in the meta-analysis were retrospective cohort 333 
studies, inherently limited in their study design compared to prospective or randomized 334 
controlled trials studies. Most studies did not distinguish etiology of SGA infants, whether 335 
constitutional versus pathologic, but the benefits and risks of ACS likely vary according to their 336 
physiology. As a result of variable definitions for SGA, we were unable to perform a subgroup 337 
analysis based on etiology of SGA or to evaluate for differences in the primary or secondary 338 
outcomes for more or less severely growth-restricted infants (for example, less than the fifth 339 
percentile versus less than the tenth percentile). Missing data for secondary outcomes, and 340 
variable ways in which data were reported or outcomes were defined, also limited data synthesis. 341 
Gestational age at delivery was highly variable and individual studies included neonates over a 342 
broad range of gestational ages, thus limiting our ability to perform subgroup analysis comparing 343 
outcomes among very early preterm (less than 28 or 32 weeks’ gestation, for example) versus 344 
preterm infants at more advanced gestational ages (32 to 34 weeks’ gestation). Similarly, 345 
heterogeneity in type of steroid used, betamethasone versus dexamethasone, limited subgroup 346 
analysis to determine which may be preferential in SGA infants. Few studies reported on what 347 
percentage of infants, if any, received a rescue course of ACS, nor did they report on the average 348 
time interval from ACS administration to infant delivery, specifically how close the timing of 349 
ACS administration was within the optimal window of 48 hours to within seven days of delivery. 350 
However, five of the sixteen included studies did exclude infants with suboptimal or partial ACS 351 
administration less than 24 hours before birth or greater than 7 days before delivery.  352 
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Future studies should further evaluate the effect of ACS administration on SGA infants in 353 
the late preterm period from 34 to 37 weeks and in non-singleton pregnancies, as data on ACS 354 
use in late preterm and multiple gestations is limited. In fact, the majority of studies excluded 355 
multiple gestations. More expansive investigation is also needed to further identify the effect of 356 
ACS on long term neurodevelopmental childhood outcomes in SGA infants, outcomes among 357 
constitutionally versus pathologically growth-restricted infants who receive ACS, and the benefit 358 
or harm of repeated or rescue doses of steroids in SGA infants delivered preterm. 359 
 360 
Conclusions and Implications 361 
 Despite these limitations, our findings suggest ACS administration among preterm SGA 362 
infants could be beneficial in reducing neonatal mortality. Our study provides evidence-based 363 
support for the continued clinical use of ACS as the standard of care for reduction of neonatal 364 
mortality among infants at risk of preterm birth in the next seven days, including the SGA 365 
population, in accordance with current guidance set for by the American College of Obstetricians 366 
and Gynecologists.43 Although a large randomized-controlled trial (RCT) would provide a higher 367 
level of evidence and reduce the effect of bias and heterogeneity on study outcomes, an RCT is 368 
likely not feasible to evaluate the effect of ACS administration in SGA infants due to both ethical 369 
reasons and patient preference for an intervention that is likely to be beneficial. Our meta-370 
analysis of thirteen observational studies provides the highest level of evidence currently 371 
available demonstrating benefit of ACS administration for reducing neonatal mortality in SGA 372 
infants at risk of preterm delivery.  373 
 374 
 375 
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FIGURE LEGENDS 522 
 523 
Figure 1. Flow Chart of the Literature Review 524 
Flow chart demonstrates the literature search, including inclusion and exclusion of selected 525 
studies. 526 
 527 
Figure 2. Forest Plots for Neonatal Mortality  528 
Forest plot demonstrates a significant reduction in neonatal mortality for SGA infants that 529 
received ACS. 530 
 531 
Figure 3. Funnel Plot for Publication Bias for Overall Mortality 532 
Funnel plot demonstrates symmetry for studies that reported overall mortality, suggesting a lack 533 
of publication bias.  534 
 535 
Figure 4. Forest Plots for Neonatal Mortality by Study Year 536 
Forest plot demonstrates a significant reduction in neonatal mortality for SGA infants that 537 
received ACS among studies that followed patients after 2010, but no significant difference in 538 
mortality among studies that followed patients up to 2010. 539 
 540 
Supplementary Figure 1. Forest Plot for RDS 541 
Forest plot demonstrates no significant reduction in RDS with ACS administration to SGA 542 
infants.  543 
 544 
Supplementary Figure 2. Forest Plot for NEC 545 
Forest plot demonstrates no significant reduction in NEC with ACS administration to SGA 546 
infants.  547 
 548 
Supplementary Figure 3. Forest Plot for IVH and/or PVL 549 
Forest plot demonstrates no significant reduction in IVH and/or PVL with ACS administration to 550 
SGA infants.  551 
 552 
Supplementary Figure 4. Forest Plot for BPD or CLD  553 
Forest plot demonstrates no significant reduction in BPD or CLD with ACS administration to 554 
SGA infants.  555 
 556 
Supplementary Figure 5. Forest Plot for Neonatal Sepsis 557 
Forest plot demonstrates no significant reduction in neonatal sepsis with ACS administration to 558 










Table 1. Baseline Study Characteristics 
Author  Publication year 
(study years) 
 





SGA defined Number of SGA 
infants  
(n) 
Number of SGA 
infants  
receiving ACS  
(n) 
Number of SGA 
infants not 




Korea Retrospective cohort 29-34 D BW <10%ile 82 45  37  
Collaborative Study Group 






China Retrospective cohort 24-34 - - 602 - - 
Melamed 2016 
(2010-2014) 
Canada Retrospective cohort 24-33w6d B or D BW <10%ile 918 698 220 
Hoellen 2016 
(2000-2011) 
Germany Retrospective cohort 22w5d-29w6d - early onset FGR <32weeks and 
BW <10%ile 
92 58 23 
Riskin-Mashiah 2015 
(1995-2012) 
Israel Retrospective cohort 24-31 - BW <10%ile 1771 1246 525 
Griffin  2015 
(2005-2012) 
United States Retrospective cohort 22-29w6d - BW <1%ile 648 271 377 
Ishikawa 2015 
(2003-2007) 
Japan Retrospective cohort 22-33w6d B BW <10%ile 1929 719 1210 
Mitsiakos 2013 
(-) 
Canada Retrospective cohort 24-31w6d B BW <10%ile 149 87 62 
van Stralen 2009 
(2001-2005) 
Netherlands Retrospective cohort <34 B BW <3%ile 88 54 34 
Torrance 2007 
(1999-2003) 
Netherlands Retrospective cohort <34 B Abnormal PI, UA or MCA 
dopplers  
165 146 19 
Foix-L’Helias 2005 
(1993-1996) 
France Retrospective cohort 24-31 - FGR antenatally suspected and 
BW <10%ile 
151 96 55 
Schaap 2001 
(1984-1991) 
Netherlands Case-control 26-31 B fundal height and biometry less 
than dates; placental dysfunction 
confirmed on histopathology 
124 62 62 
Bernstein 1999 
(1991-1996) 
Canada/United States Retrospective cohort 25-30 - BW <10%ile 1720 937 783 
Elimian 1999 
(1990-1997) 
United States Retrospective cohort - B BW <10%ile 220 63 157 
Ley 1997 
(1985-94) 
Sweden Retrospective cohort 25-32 - Use of growth curve based on 
longitudinal EFW on US 
234 117 117 
Spinillo 1995 
(1988-1993) 
Italy Prospective cohort <35 B or D BW<10% and AC or HC <10%ile 
on US 
96 32 64 
*SGA=small-for-gestational age, ACS=antenatal corticosteroids, B=betamethasone, D=dexamethasone, BW=birth weight, PI=pulsatility index, UA=umbilical artery, MCA=middle cerebral artery, FGR=fetal growth restriction, EFW=estimated fetal weight,  
US= ultrasound, AC=abdominal circumference, HC=head circumference 
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receiving ACS  
(n) 
Number of SGA 
infants not 
receiving ACS  
(n) 
Mean maternal  
age  


















































































































































































































































































































*SGA=small-for-gestational age, ACS=antenatal corticosteroids, SD=standard deviation, CSGRDSPI=Collaborative Study Group for Respiratory Distress in Preterm Infants, +ACS=infants received antenatal corticosteroids,  
-ACS=infants did not receive antenatal corticosteroids 
† Chorioamnionitis is clinically diagnosed unless otherwise specified 
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Mean gestational age  





























































































































































































































































































































































*SGA=small-for-gestational age, ACS=antenatal corticosteroids, SD=standard deviation, CSGRDSPI=Collaborative Study Group for Respiratory Distress in Preterm Infants, +ACS=infants received antenatal corticosteroids,  
-ACS=infants did not receive antenatal corticosteroids 
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937 783 - - 
 







































117 117 OR 0.53 
(95% CI 0.21-1.32) 
OR 1.20 









         
Spinillo  
(1995) 
































*SGA=small-for-gestational age, ACS=antenatal corticosteroids, RDS=respiratory distress syndrome, BPD=bronchopulmonary dysplasia, CLD=chronic lung disease, IVH=intraventricular hemorrhage, PVL=periventricular leukomalacia, NEC=necrotizing enterocolitis,  
CSGRDSPI=Collaborative Study Group for Respiratory Distress in Preterm Infants, +ACS=infants received antenatal corticosteroids, -ACS=infants did not receive antenatal corticosteroids, OR=odds ratios, CI=confidence interval    
† Raw data for neonatal outcomes according to ACS administration was not reported for 3 studies; only odds ratios with 95% confidence intervals were reported in these studies comparing SGA infants that received ACS to those that did not receive ACS 
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Supplementary Table 1. Study Outcome Definitions 
 
Study Outcome Definition 
Neonatal mortality The percentage of infants who die either during their hospital stay after delivery or up to three 
years of life. 
 
Composite neonatal morbidity A composite outcome of the percentage of infants affected by any of the included adverse 
perinatal outcomes: RDS, BPD/CLD, IVH, PVL, NEC or neonatal sepsis. 
 
Respiratory distress syndrome (RDS) Defined based on clinical criteria, such as tachypnea, chest wall retractions, grunting, and 
supplemental oxygen requirement, and based on radiological criteria with poor lung expansion on 
chest x-ray classified as RDS 
 
Bronchopulmonary dysplasia (BPD)/  
chronic lung disease of prematurity (CLD) 
Oxygen supplementation required at 36 weeks’ postmenstrual age or the presence of chronic 
respiratory distress and oxygen requirement beyond 28 days of life accompanied by a chest 
radiograph that showed chronic abnormalities such as persistent streaks of increased density in 
both lungs interspersed with normal or hyperlucent areas 
 
Intraventricular hemorrhage (IVH) Bleeding within the ventricular system of the brain as defined by Papile’s classification,21 with 
the majority of studies including grades 3 and 4 
 
Periventricular leukomalacia (PVL) Necrosis of white matter near the lateral ventricles diagnosed by cranial ultrasonography 
 
Necrotizing enterocolitis (NEC) Intestines in premature infants become infected causing partial or full-thickness necrosis of the 
bowel 
 





























Ovid Medline   
Date Searched: 6/11/2019; 5/13/20  
Applied Database Supplied Limits: n/a   
Number of Results:  2643; 2783  
  
Search strategy was re-run on May 13, 2020. 140 additional citations found  
  
Full Search Strategy:   
(ACS).ti,ab. OR ((antenatal* OR prenatal*) ADJ3 (corticosteroid* OR corticoid* OR glucocorticoid* OR glucorticoid* OR steroid* OR CST)).ti,ab. OR 
((adrenal cortex) ADJ1 (hormone*) ADJ2 (prenatal* OR antenatal*)).ti,ab. OR ((prenatal* OR antenatal*) ADJ2 (Betamethasone OR adbeon OR becasone 
OR beprogel OR beta methason OR betacortril OR betadexamethasone OR betametasone OR betamethasolone OR betamethazone OR betnasol OR betnelan 
OR betnesol OR betnovate OR betsolan OR betsolon OR betsopart OR celestan OR celestene OR celeston* OR cellestoderm OR cidoten OR dermobet OR 
diprolen OR flubenisolone OR flubenisolonvalerate OR methasone OR rinderon OR walacort)).ti,ab. OR ((prenatal* OR antenatal*) ADJ2 (Dexamethasone 
OR adrecort OR adrenocot OR aeroseb dex OR aflucoson* OR alfalyl OR anaflogistico OR arcodexan* OR artrosone OR auxison OR azium OR bidexol 
OR calonat OR cebedex OR cetadexon OR colofoam OR corsona OR cortastat OR cortidex* OR cortidexason OR cortidrona OR cortidrone OR 
cortisumman OR dacortina fuerte OR dacortine fuerte OR dalalone OR danasone OR de-sone la OR decacortin OR decadeltosona OR decadeltosone OR 
decaderm OR decadion OR decadran OR decadron* OR decaesadril OR decaject OR decameth* OR decasone OR decaspray OR decasterolone OR decdan 
OR decilone OR decofluor OR dectancyl OR dekacort OR delladec OR deltafluoren* OR dergramin OR deronil OR desacort OR desacortone OR desadrene 
OR desalark OR desameton* OR desigdron OR dexa cortisyl OR dexa dabrosan OR dexa korti OR dexa scherosan OR dexa scherozon OR dexa scherozone 
OR dexa p OR dexacen 4 OR dexachel OR dexacort* OR dexadabroson OR dexadecadrol OR dexadrol OR dexagel OR dexagen OR dexahelvacort OR 
dexakorti OR dexalien OR dexalocal OR dexame OR dexamecortin OR dexameson* OR dexametason* OR dexamonozon OR dexan* OR dexapot OR 
dexascheroson OR dexascherozon* OR dexason* OR dexinoral OR dexionil OR dexmethsone OR dexona OR dexone OR dexpak taperpak OR dextelan OR 
dextrasone OR dexycu OR dezone OR dibasona OR dexamethasone OR esacortene OR exadion OR exadione OR firmalone OR fluormethyl prednisolone 
OR fluormethylprednisolon* OR fluormone OR fluorocort OR fluorodelta OR fluoromethylprednisolone OR fortecortin OR gammacorten* OR 
grosodexon* OR hexadecadiol OR hexadecadrol OR hexadiol OR hexadrol OR isnacort OR isopto* OR lokalison f OR loverine OR luxazone OR 
marvidione OR maxidex OR mediamethasone OR megacortin OR mephameson* OR metasolon* OR methazon* OR methylfluorprednisolone OR metisone 
lafi OR mexasone OR millicorten* OR mymethasone OR neoforderx OR neofordex OR nisomethasona OR novocort OR oftan dexa OR opticorten OR 
opticortinol OR oradexan OR oradexon* OR orgadrone OR ozurdex OR pidexon OR policort OR posurdex OR predni f OR prednisolone f OR prodexona 
OR prodexone OR sanamethasone OR santenson OR santeson OR sawasone OR solurex OR spoloven OR sterasone OR thilodexine OR tobradex OR 
triamcimetil OR vexamet OR visumetazone OR visumethazone)).ti,ab. OR (((prenatal* OR antenatal*).hw. OR ((prenatal* OR antenatal* OR fetal OR 
foetal OR intrauterine OR maternal) ADJ1 (drug exposure)).ti,ab.) AND (exp adrenal cortex hormones/ OR exp glucocorticoids/ OR exp betamethasone/ OR 
exp dexamethasone/ OR ((adrenal cortex) ADJ1 (hormone*)).ti,ab. OR (Corticotherap* OR corticosteroid* OR corticoid* OR Glucocorticoid* OR 
glucorticoid* OR Betamethasone OR adbeon OR becasone OR beprogel OR beta methason OR betacortril OR betadexamethasone OR betametasone OR 
betamethasolone OR betamethazone OR betnasol OR betnelan OR betnesol OR betnovate OR betsolan OR betsolon OR betsopart OR celestan OR celestene 
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OR celeston* OR cellestoderm OR cidoten OR dermobet OR diprolen OR flubenisolone OR flubenisolonvalerate OR methasone OR rinderon OR walacort 
OR Dexamethasone OR adrecort OR adrenocot OR aeroseb dex OR aflucoson* OR alfalyl OR anaflogistico OR arcodexan* OR artrosone OR auxison OR 
azium OR bidexol OR calonat OR cebedex OR cetadexon OR colofoam OR corsona OR cortastat OR cortidex* OR cortidexason OR cortidrona OR 
cortidrone OR cortisumman OR dacortina fuerte OR dacortine fuerte OR dalalone OR danasone OR de-sone la OR decacortin OR decadeltosona OR 
decadeltosone OR decaderm OR decadion OR decadran OR decadron* OR decaesadril OR decaject OR decameth* OR decasone OR decaspray OR 
decasterolone OR decdan OR decilone OR decofluor OR dectancyl OR dekacort OR delladec OR deltafluoren* OR dergramin OR deronil OR desacort OR 
desacortone OR desadrene OR desalark OR desameton* OR desigdron OR dexa cortisyl OR dexa dabrosan OR dexa korti OR dexa scherosan OR dexa 
scherozon OR dexa scherozone OR dexa p OR dexacen 4 OR dexachel OR dexacort* OR dexadabroson OR dexadecadrol OR dexadrol OR dexagel OR 
dexagen OR dexahelvacort OR dexakorti OR dexalien OR dexalocal OR dexame OR dexamecortin OR dexameson* OR dexametason* OR dexamonozon 
OR dexan* OR dexapot OR dexascheroson OR dexascherozon* OR dexason* OR dexinoral OR dexionil OR dexmethsone OR dexona OR dexone OR 
dexpak taperpak OR dextelan OR dextrasone OR dexycu OR dezone OR dibasona OR dexamethasone OR esacortene OR exadion OR exadione OR 
firmalone OR fluormethyl prednisolone OR fluormethylprednisolon* OR fluormone OR fluorocort OR fluorodelta OR fluoromethylprednisolone OR 
fortecortin OR gammacorten* OR grosodexon* OR hexadecadiol OR hexadecadrol OR hexadiol OR hexadrol OR isnacort OR isopto* OR lokalison f OR 
loverine OR luxazone OR marvidione OR maxidex OR mediamethasone OR megacortin OR mephameson* OR metasolon* OR methazon* 
OR methylfluorprednisolone OR metisone lafi OR mexasone OR millicorten* OR mymethasone OR neoforderx OR neofordex OR nisomethasona OR 
novocort OR oftan dexa OR opticorten OR opticortinol OR oradexan OR oradexon* OR orgadrone OR ozurdex OR pidexon OR policort OR posurdex OR 
predni f OR prednisolone f OR prodexona OR prodexone OR sanamethasone OR santenson OR santeson OR sawasone OR solurex OR spoloven OR 
sterasone OR thilodexine OR tobradex OR triamcimetil OR vexamet OR visumetazone OR visumethazone).ti,ab.))   
AND   
(exp Fetal Growth Retardation/ OR exp Infant, Low Birth Weight/ OR exp Obstetric Labor, Premature OR exp Infant, Premature/ OR exp Birth Weight/ OR 
(birthweight* OR prematuritas OR small for gestational age).ti,ab. OR ((premature OR preterm*) ADJ2 (birth* OR labor* OR labour* OR delivery OR 
deliveries OR infant* OR neonate* OR newborn* OR baby OR babies OR childbirth* OR fetus*)).ti,ab. OR ((pre-mature OR pre-term*) ADJ2 (birth* OR 
labor* OR labour* OR delivery OR deliveries OR infant* OR neonate* OR newborn* OR baby OR babies OR childbirth*)).ti,ab. OR ((birth* OR neonat* 
OR newborn OR infant*) ADJ1 (weight* OR underweight)).ti,ab. OR ((SGA) ADJ1 (neonate OR infant* OR fetus* OR newborn*)).ti,ab. OR ((small for 
date) ADJ3 (baby* OR babies OR infant* OR neonat* OR fetus*)).ti,ab. OR ((small for age) ADJ3 (baby* OR babies OR infant* OR neonat* OR 
fetus*)).ti,ab. OR ((fetal OR neonat* OR infant* OR fetus OR foetal OR in utero OR intrauterine OR prenatal) ADJ2 (growth) ADJ2 (restrict* OR 
retardation OR disorder*)).ti,ab.) NOT ((exp Animals/) not (exp Animals/ and exp Humans/))  
  
Embase  
Date Searched: 6/11/19, 5/13/20   
Applied Database Supplied Limits: n/a   
Number of Results:  4184; 4422  
  
Search was re-run on May 13, 2020. Additional 238 results.   
  
Full Search Strategy:  
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'prematurity'/exp OR 'birth weight'/exp OR 'intrauterine growth retardation'/exp OR 'premature labor'/exp OR ‘premature birth’/de OR ‘fetal growth 
retardation’/de OR (birthweight* OR prematuritas OR ‘small for gestational age’):ti,ab OR ((premature OR preterm*) NEAR/2 (birth* OR labor* 
OR labour* OR delivery OR deliveries OR infant* OR neonate* OR newborn* OR baby OR babies OR childbirth* OR fetus*)):ti,ab OR ((pre-mature OR 
pre-term*) NEAR/2 (birth* OR labor* OR labour* OR delivery OR deliveries OR infant* OR neonate* OR newborn* OR baby OR babies OR 
childbirth*)):ti,ab OR ((birth* OR neonat* OR newborn OR infant*) NEAR/1 (weight* OR underweight)):ti,ab OR ((SGA) NEAR/1 (neonate OR infant* 
OR fetus* OR newborn*)):ti,ab OR ((‘small for date’) NEAR/3 (baby* OR babies OR infant* OR neonat* OR fetus*)):ti,ab OR ((‘small for age’) NEAR/3 
(baby* OR babies OR infant* OR neonat* OR fetus*)):ti,ab OR ((fetal OR neonat* OR infant* OR fetus OR foetal OR ‘in utero’ OR intrauterine OR 
prenatal) NEAR/2 (growth) NEAR/2 (restrict* OR retardation OR disorder*)):ti,ab  
AND   
((‘antenatal corticosteroid therapy’/de OR ACS:ti,ab OR   
((antenatal* OR prenatal*) NEAR/3 (corticosteroid* OR corticoid* OR glucocorticoid* OR glucorticoid* OR steroid* OR CST)):ti,ab OR ((‘adrenal 
cortex’) NEAR/1 (hormone*) NEAR/2 (prenatal* OR antenatal*)):ti,ab OR   
((prenatal* OR antenatal*) NEAR/2 (Betamethasone OR adbeon OR becasone OR beprogel OR 'beta methason' 
OR betacortril OR betadexamethasone OR betametasone OR betamethasolone OR betamethazone OR betnasol OR betnelan OR betnesol OR betnovate OR 
betsolan OR betsolon OR betsopart OR celestan OR celestene OR celeston* 
OR cellestoderm OR cidoten OR dermobet OR diprolen OR flubenisolone OR flubenisolonvalerate OR methasone OR rinderon OR walacort)):ti,ab OR   
((prenatal* OR antenatal*) NEAR/2 (Dexamethasone OR adrecort OR adrenocot OR 'aeroseb dex' OR aflucoson* OR alfalyl OR anaflogistico OR 
arcodexan* OR artrosone OR auxison OR azium OR bidexol OR calonat OR cebedex OR cetadexon OR colofoam OR corsona OR cortastat OR cortidex* 
OR cortidexason OR cortidrona OR cortidrone OR cortisumman OR 'dacortina fuerte' OR 'dacortine fuerte' OR dalalone OR danasone OR 'de-sone la' OR 
decacortin OR decadeltosona OR decadeltosone OR decaderm OR decadion OR decadran OR decadron* OR decaesadril OR decaject OR decameth* OR 
decasone OR decaspray OR decasterolone OR decdan OR decilone OR decofluor OR dectancyl OR dekacort OR delladec OR deltafluoren* OR dergramin 
OR deronil OR desacort OR desacortone OR desadrene OR desalark OR desameton* OR desigdron OR 'dexa cortisyl' OR 'dexa dabrosan' OR 'dexa korti' 
OR 'dexa scherosan' OR 'dexa scherozon' OR 'dexa scherozone' OR 'dexa p' OR 'dexacen 4' OR dexachel OR dexacort* OR dexadabroson OR dexadecadrol 
OR dexadrol OR dexagel OR dexagen OR dexahelvacort OR dexakorti OR dexalien OR dexalocal OR dexame OR dexamecortin OR dexameson* OR 
dexametason* OR dexamonozon OR dexan* OR dexapot OR dexascheroson OR dexascherozon* OR dexason* OR dexinoral OR dexionil OR dexmethsone 
OR dexona OR dexone OR 'dexpak taperpak' OR dextelan OR dextrasone OR dexycu OR dezone OR dibasona OR dexamethasone OR esacortene OR 
exadion OR exadione OR firmalone OR 'fluormethyl prednisolone' OR fluormethylprednisolon* OR fluormone OR fluorocort OR fluorodelta OR 
fluoromethylprednisolone OR fortecortin OR gammacorten* OR grosodexon* OR hexadecadiol OR hexadecadrol OR hexadiol OR hexadrol OR isnacort 
OR isopto* OR 'lokalison f' OR loverine OR luxazone OR marvidione OR maxidex OR mediamethasone OR megacortin OR mephameson* OR metasolon* 
OR methazon* OR methylfluorprednisolone OR 'metisone lafi' OR mexasone OR millicorten* OR mymethasone OR neoforderx OR neofordex OR 
nisomethasona OR novocort OR 'oftan dexa' OR opticorten OR opticortinol OR oradexan OR oradexon* OR orgadrone OR ozurdex OR pidexon OR 
policort OR posurdex OR 'predni f' OR 'prednisolone f' OR prodexona OR prodexone OR sanamethasone OR santenson OR santeson OR sawasone OR 
solurex OR spoloven OR sterasone OR thilodexine OR tobradex OR triamcimetil OR vexamet OR visumetazone OR visumethazone)):ti,ab)   
OR   
(('prenatal drug exposure'/exp OR (prenatal* OR antenatal*):de OR ((prenatal* OR antenatal* OR fetal OR foetal OR intrauterine OR maternal) NEAR/1 
(‘drug exposure’)):ti,ab) AND ('corticosteroid therapy'/exp OR ‘betamethasone'/exp OR 'dexamethasone'/exp OR ((‘adrenal cortex’) NEAR/1 
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(hormone*)):ti,ab OR (Corticotherap* OR corticosteroid* OR corticoid* OR Glucocorticoid* OR glucorticoid* OR Betamethasone OR adbeon OR 
becasone OR beprogel OR 'beta methason' OR betacortril OR betadexamethasone OR betametasone OR betamethasolone OR betamethazone OR betnasol 
OR betnelan OR betnesol OR betnovate OR betsolan OR betsolon OR betsopart OR celestan OR celestene OR celeston* OR cellestoderm OR cidoten OR 
dermobet OR diprolen OR flubenisolone OR flubenisolonvalerate OR methasone OR rinderon OR walacort OR Dexamethasone OR adrecort OR adrenocot 
OR 'aeroseb dex' OR aflucoson* OR alfalyl OR anaflogistico OR arcodexan* OR artrosone OR auxison OR azium OR bidexol OR calonat OR cebedex OR 
cetadexon OR colofoam OR corsona OR cortastat OR cortidex* OR cortidexason OR cortidrona OR cortidrone OR cortisumman OR 'dacortina fuerte' OR 
'dacortine fuerte' OR dalalone OR danasone OR 'de-sone la' OR decacortin OR decadeltosona OR decadeltosone OR decaderm OR decadion OR decadran 
OR decadron* OR decaesadril OR decaject OR decameth* OR decasone OR decaspray OR decasterolone OR decdan OR decilone OR decofluor OR 
dectancyl OR dekacort OR delladec OR deltafluoren* OR dergramin OR deronil OR desacort OR desacortone OR desadrene OR desalark OR desameton* 
OR desigdron OR 'dexa cortisyl' OR 'dexa dabrosan' OR 'dexa korti' OR 'dexa scherosan' OR 'dexa scherozon' OR 'dexa scherozone' OR 'dexa p' OR 
'dexacen 4' OR dexachel OR dexacort* OR dexadabroson OR dexadecadrol OR dexadrol OR dexagel OR dexagen OR dexahelvacort OR dexakorti OR 
dexalien OR dexalocal OR dexame OR dexamecortin OR dexameson* OR dexametason* OR dexamonozon OR dexan* OR dexapot OR dexascheroson OR 
dexascherozon* OR dexason* OR dexinoral OR dexionil OR dexmethsone OR dexona OR dexone OR 'dexpak taperpak' OR dextelan OR dextrasone OR 
dexycu OR dezone OR dibasona OR dexamethasone OR esacortene OR exadion OR exadione OR firmalone OR 'fluormethyl prednisolone' OR 
fluormethylprednisolon* OR fluormone OR fluorocort OR fluorodelta OR fluoromethylprednisolone OR fortecortin OR gammacorten* OR grosodexon* 
OR hexadecadiol OR hexadecadrol OR hexadiol OR hexadrol OR isnacort OR isopto* OR 'lokalison f' OR loverine OR luxazone OR marvidione OR 
maxidex OR mediamethasone OR megacortin OR mephameson* OR metasolon* OR methazon* OR methylfluorprednisolone OR 'metisone lafi' OR 
mexasone OR millicorten* OR mymethasone OR neoforderx OR neofordex OR nisomethasona OR novocort OR 'oftan dexa' OR opticorten OR opticortinol 
OR oradexan OR oradexon* OR orgadrone OR ozurdex OR pidexon OR policort OR posurdex OR 'predni f' OR 'prednisolone f' OR prodexona OR 
prodexone OR sanamethasone OR santenson OR santeson OR sawasone OR solurex OR spoloven OR sterasone OR thilodexine OR tobradex OR 




Date Searched: 6/11/19; 5/13/20  
Applied Database Supplied Limits: n/a   
Number of Results from each database in Cochrane  
CDSR: 34; 27   
*0 for last year.  
  
CENTRAL: 497; 498   
*35 found for 2019 -2020 and exported.   
Cochrane Protocols : 2  
Editorials: 1   
Clinical Answers: 1   
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Search strategy was re-run on May 13, 2020. 8 additional records found (529 total).   
Full Search Strategy:  
1. [mh “fetal growth retardation”] OR [mh “Infant, Low Birth Weight”] OR [mh “Obstetric Labor, Premature”] OR [mh “Infant, Premature”] OR 
[mh “Birth Weight”] OR   
(birthweight* OR prematuritas OR ‘small for gestational age’):ti,ab OR   
((premature OR preterm*) NEAR/2 (birth* OR labor* OR labour* OR delivery OR deliveries OR infant* OR neonate* OR newborn* OR baby OR babies 
OR childbirth* OR fetus*)):ti,ab OR   
((pre-mature OR pre-term*) NEAR/2 (birth* OR labor* OR labour* OR delivery OR deliveries OR infant* OR neonate* OR newborn* OR baby OR babies 
OR childbirth*)):ti,ab OR   
((birth* OR neonat* OR newborn OR infant*) NEAR/1 (weight* OR underweight)):ti,ab OR   
((SGA) NEAR/1 (neonate OR infant* OR fetus* OR newborn*)):ti,ab OR   
((‘small for date’) NEAR/3 (baby* OR babies OR infant* OR neonat* OR fetus*)):ti,ab OR   
((‘small for age’) NEAR/3 (baby* OR babies OR infant* OR neonat* OR fetus*)):ti,ab OR   




2. ACS:ti,ab OR ((antenatal* OR prenatal*) NEAR/3 (corticosteroid* OR corticoid* OR glucocorticoid* OR glucorticoid* OR steroid* OR 
CST)):ti,ab OR   
((“adrenal cortex”) NEAR/1 (hormone*) NEAR/2 (prenatal* OR antenatal*)):ti,ab OR   
((prenatal* OR antenatal*) NEAR/2 (Betamethasone OR adbeon OR becasone OR beprogel OR “beta methason” 
OR betacortril OR betadexamethasone OR betametasone OR betamethasolone OR betamethazone OR betnasol OR betnelan OR betnesol OR betnovate OR 
betsolan OR betsolon OR betsopart OR celestan OR celestene OR celeston* 
OR cellestoderm OR cidoten OR dermobet OR diprolen OR flubenisolone OR flubenisolonvalerate OR methasone OR rinderon OR walacort)):ti,ab OR   
((prenatal* OR antenatal*) NEAR/2 (Dexamethasone OR adrecort OR adrenocot OR “aeroseb dex” OR aflucoson* OR alfalyl OR anaflogistico OR 
arcodexan* OR artrosone OR auxison OR azium OR bidexol OR calonat OR cebedex OR cetadexon OR colofoam OR corsona OR cortastat OR cortidex* 
OR cortidexason OR cortidrona OR cortidrone OR cortisumman OR “dacortina fuerte” OR “dacortine fuerte” OR dalalone OR danasone OR “de-sone la” 
OR decacortin OR decadeltosona OR decadeltosone OR decaderm OR decadion OR decadran OR decadron* OR decaesadril OR decaject OR decameth* 
OR decasone OR decaspray OR decasterolone OR decdan OR decilone OR decofluor OR dectancyl OR dekacort OR delladec OR deltafluoren* OR 
dergramin OR deronil OR desacort OR desacortone OR desadrene OR desalark OR desameton* OR desigdron OR “dexa cortisyl” OR “dexa dabrosan” OR 
“dexa korti” OR “dexa scherosan” OR “dexa scherozon” OR “dexa scherozone” OR “dexa p” OR “dexacen 4” OR dexachel OR dexacort* OR 
dexadabroson OR dexadecadrol OR dexadrol OR dexagel OR dexagen OR dexahelvacort OR dexakorti OR dexalien OR dexalocal OR dexame OR 
dexamecortin OR dexameson* OR dexametason* OR dexamonozon OR dexan* OR dexapot OR dexascheroson OR dexascherozon* OR dexason* OR 
dexinoral OR dexionil OR dexmethsone OR dexona OR dexone OR “dexpak taperpak” OR dextelan OR dextrasone OR dexycu OR dezone OR dibasona 
OR dexamethasone OR esacortene OR exadion OR exadione OR firmalone OR “fluormethyl prednisolone” OR fluormethylprednisolon* OR fluormone OR 
fluorocort OR fluorodelta OR fluoromethylprednisolone OR fortecortin OR gammacorten* OR grosodexon* OR hexadecadiol OR hexadecadrol OR 
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hexadiol OR hexadrol OR isnacort OR isopto* OR “lokalison f” OR loverine OR luxazone OR marvidione OR maxidex OR mediamethasone OR 
megacortin OR mephameson* OR metasolon* OR methazon* OR methylfluorprednisolone OR “metisone lafi” OR mexasone OR millicorten* OR 
mymethasone OR neoforderx OR neofordex OR nisomethasona OR novocort OR “oftan dexa” OR opticorten OR opticortinol OR oradexan OR oradexon* 
OR orgadrone OR ozurdex OR pidexon OR policort OR posurdex OR “predni f” OR “prednisolone f” OR prodexona OR prodexone OR sanamethasone OR 
santenson OR santeson OR sawasone OR solurex OR spoloven OR sterasone OR thilodexine OR tobradex OR triamcimetil OR vexamet OR visumetazone 
OR visumethazone)):ti,ab  
  
3. (prenatal* OR antenatal*):kw OR ((prenatal* OR antenatal* OR fetal OR foetal OR intrauterine OR maternal) NEAR/1 (“drug exposure”)):ti,ab  
4. ([mh “adrenal cortex hormones”] OR [mh glucocorticoids] OR [mh betamethasone] OR [mh dexamethasone] OR ((“adrenal cortex”) NEAR/1 
(hormone*)):ti,ab OR (Corticotherap* OR corticosteroid* OR corticoid* OR Glucocorticoid* OR glucorticoid* OR Betamethasone OR adbeon OR 
becasone OR beprogel OR “beta methason” OR betacortril OR betadexamethasone OR betametasone OR betamethasolone OR betamethazone OR 
betnasol OR betnelan OR betnesol OR betnovate OR betsolan OR betsolon OR betsopart OR celestan OR celestene OR celeston* OR cellestoderm OR 
cidoten OR dermobet OR diprolen OR flubenisolone OR flubenisolonvalerate OR methasone OR rinderon OR walacort OR Dexamethasone OR adrecort 
OR adrenocot OR “aeroseb dex” OR aflucoson* OR alfalyl OR anaflogistico OR arcodexan* OR artrosone OR auxison OR azium OR bidexol OR 
calonat OR cebedex OR cetadexon OR colofoam OR corsona OR cortastat OR cortidex* OR cortidexason OR cortidrona OR cortidrone OR 
cortisumman OR “dacortina fuerte” OR “dacortine fuerte” OR dalalone OR danasone OR “de-sone la” OR decacortin OR decadeltosona OR 
decadeltosone OR decaderm OR decadion OR decadran OR decadron* OR decaesadril OR decaject OR decameth* OR decasone OR decaspray OR 
decasterolone OR decdan OR decilone OR decofluor OR dectancyl OR dekacort OR delladec OR deltafluoren* OR dergramin OR deronil OR desacort 
OR desacortone OR desadrene OR desalark OR desameton* OR desigdron OR “dexa cortisyl” OR “dexa dabrosan” OR “dexa korti” OR “dexa 
scherosan” OR “dexa scherozon” OR “dexa scherozone” OR “dexa p” OR “dexacen 4” OR dexachel OR dexacort* OR dexadabroson OR dexadecadrol 
OR dexadrol OR dexagel OR dexagen OR dexahelvacort OR dexakorti OR dexalien OR dexalocal OR dexame OR dexamecortin OR dexameson* OR 
dexametason* OR dexamonozon OR dexan* OR dexapot OR dexascheroson OR dexascherozon* OR dexason* OR dexinoral OR dexionil OR 
dexmethsone OR dexona OR dexone OR “dexpak taperpak” OR dextelan OR dextrasone OR dexycu OR dezone OR dibasona OR dexamethasone OR 
esacortene OR exadion OR exadione OR firmalone OR “fluormethyl prednisolone” OR fluormethylprednisolon* OR fluormone OR fluorocort OR 
fluorodelta OR fluoromethylprednisolone OR fortecortin OR gammacorten* OR grosodexon* OR hexadecadiol OR hexadecadrol OR hexadiol OR 
hexadrol OR isnacort OR isopto* OR “lokalison f” OR loverine OR luxazone OR marvidione OR maxidex OR mediamethasone OR megacortin OR 
mephameson* OR metasolon* OR methazon* OR methylfluorprednisolone OR “metisone lafi” OR mexasone OR millicorten* OR mymethasone OR 
neoforderx OR neofordex OR nisomethasona OR novocort OR “oftan dexa” OR opticorten OR opticortinol OR oradexan OR oradexon* OR orgadrone 
OR ozurdex OR pidexon OR policort OR posurdex OR “predni f” OR “prednisolone f” OR prodexona OR prodexone OR sanamethasone OR santenson 
OR santeson OR sawasone OR solurex OR spoloven OR sterasone OR thilodexine OR tobradex OR triamcimetil OR vexamet OR visumetazone OR 
visumethazone):ti,ab)  
5. #3 AND #4  
6. #5 OR #2   
7. #6 AND #1  
  
  





Date Searched: 6/11/19; 5/13/20   
Applied Database Supplied Limits: n/a   
Number of Results:  2778, 2911  
  
Search strategy was re-run on May 13, 2020. 133 new results.   
Full Search Strategy:  
TITLE-ABS(birthweight* OR prematuritas OR “small for gestational age” OR   
((premature OR preterm*) W/2 (birth* OR labor* OR labour* OR delivery OR deliveries OR infant* OR neonate* OR newborn* OR baby OR babies OR 
childbirth* OR fetus*)) OR   
((pre-mature OR pre-term*) W/2 (birth* OR labor* OR labour* OR delivery OR deliveries OR infant* OR neonate* OR newborn* OR baby OR babies OR 
childbirth*)) OR   
((birth* OR neonat* OR newborn OR infant*) W/1 (weight* OR underweight)) OR   
((SGA) W/1 (neonate OR infant* OR fetus* OR newborn*)) OR   
((“small for date”) W/3 (baby* OR babies OR infant* OR neonat* OR fetus*)) OR   
((“small for age”) W/3 (baby* OR babies OR infant* OR neonat* OR fetus*)) OR   
((fetal OR neonat* OR infant* OR fetus OR foetal OR “in utero” OR intrauterine OR prenatal) W/2 (growth) W/2 (restrict* OR retardation OR disorder*)))   
AND   
TITLE-ABS(ACS OR   
((antenatal* OR prenatal*) W/3 (corticosteroid* OR corticoid* OR glucocorticoid* OR glucorticoid* OR steroid* OR CST)) OR   
((“adrenal cortex”) W/1 (hormone*) W/2 (prenatal* OR antenatal*)) OR   
((prenatal* OR antenatal*) W/2 (Betamethasone OR adbeon OR becasone OR beprogel OR “beta methason” 
OR betacortril OR betadexamethasone OR betametasone OR betamethasolone OR betamethazone OR betnasol OR betnelan OR betnesol OR betnovate OR 
betsolan OR betsolon OR betsopart OR celestan OR celestene OR celeston* 
OR cellestoderm OR cidoten OR dermobet OR diprolen OR flubenisolone OR flubenisolonvalerate OR methasone OR rinderon OR walacort)) OR   
((prenatal* OR antenatal*) W/2 (Dexamethasone OR adrecort OR adrenocot OR “aeroseb dex” OR aflucoson* OR alfalyl OR anaflogistico OR arcodexan* 
OR artrosone OR auxison OR azium OR bidexol OR calonat OR cebedex OR cetadexon OR colofoam OR corsona OR cortastat OR cortidex* OR 
cortidexason OR cortidrona OR cortidrone OR cortisumman OR “dacortina fuerte” OR “dacortine fuerte” OR dalalone OR danasone OR “de-sone la” OR 
decacortin OR decadeltosona OR decadeltosone OR decaderm OR decadion OR decadran OR decadron* OR decaesadril OR decaject OR decameth* OR 
decasone OR decaspray OR decasterolone OR decdan OR decilone OR decofluor OR dectancyl OR dekacort OR delladec OR deltafluoren* OR dergramin 
OR deronil OR desacort OR desacortone OR desadrene OR desalark OR desameton* OR desigdron OR “dexa cortisyl” OR “dexa dabrosan” OR “dexa 
korti” OR “dexa scherosan” OR “dexa scherozon” OR “dexa scherozone” OR “dexa p” OR “dexacen 4” OR dexachel OR dexacort* OR dexadabroson OR 
dexadecadrol OR dexadrol OR dexagel OR dexagen OR dexahelvacort OR dexakorti OR dexalien OR dexalocal OR dexame OR dexamecortin OR 
dexameson* OR dexametason* OR dexamonozon OR dexan* OR dexapot OR dexascheroson OR dexascherozon* OR dexason* OR dexinoral OR dexionil 
OR dexmethsone OR dexona OR dexone OR “dexpak taperpak” OR dextelan OR dextrasone OR dexycu OR dezone OR dibasona OR dexamethasone OR 
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esacortene OR exadion OR exadione OR firmalone OR “fluormethyl prednisolone” OR fluormethylprednisolon* OR fluormone OR fluorocort OR 
fluorodelta OR fluoromethylprednisolone OR fortecortin OR gammacorten* OR grosodexon* OR hexadecadiol OR hexadecadrol OR hexadiol OR hexadrol 
OR isnacort OR isopto* OR “lokalison f” OR loverine OR luxazone OR marvidione OR maxidex OR mediamethasone OR megacortin OR mephameson* 
OR metasolon* OR methazon* OR methylfluorprednisolone OR “metisone lafi” OR mexasone OR millicorten* OR mymethasone OR neoforderx OR 
neofordex OR nisomethasona OR novocort OR “oftan dexa” OR opticorten OR opticortinol OR oradexan OR oradexon* OR orgadrone OR ozurdex OR 
pidexon OR policort OR posurdex OR “predni f” OR “prednisolone f” OR prodexona OR prodexone OR sanamethasone OR santenson OR santeson OR 
sawasone OR solurex OR spoloven OR sterasone OR thilodexine OR tobradex OR triamcimetil OR vexamet OR visumetazone OR visumethazone))) OR   
((KEY(prenatal* OR antenatal*) OR   
TITLE-ABS((prenatal* OR antenatal* OR fetal OR foetal OR intrauterine OR maternal) W/1 (“drug exposure”)))  
AND   
TITLE-ABS(((“adrenal cortex”) W/1 (hormone*)) OR  
Corticotherap* OR corticosteroid* OR corticoid* OR Glucocorticoid* OR glucorticoid* OR   
Betamethasone OR adbeon OR becasone OR beprogel OR “beta methason” 
OR betacortril OR betadexamethasone OR betametasone OR betamethasolone OR betamethazone OR betnasol OR betnelan OR betnesol OR betnovate OR 
betsolan OR betsolon OR betsopart OR celestan OR celestene OR celeston* 
OR cellestoderm OR cidoten OR dermobet OR diprolen OR flubenisolone OR flubenisolonvalerate OR methasone OR rinderon OR walacort OR   
Dexamethasone OR adrecort OR adrenocot OR “aeroseb dex” OR aflucoson* OR alfalyl OR anaflogistico OR arcodexan* OR artrosone OR auxison OR 
azium OR bidexol OR calonat OR cebedex OR cetadexon OR colofoam OR corsona OR cortastat OR cortidex* OR cortidexason OR cortidrona OR 
cortidrone OR cortisumman OR “dacortina fuerte” OR “dacortine fuerte” OR dalalone OR danasone OR “de-sone la” OR decacortin OR decadeltosona OR 
decadeltosone OR decaderm OR decadion OR decadran OR decadron* OR decaesadril OR decaject OR decameth* OR decasone OR decaspray OR 
decasterolone OR decdan OR decilone OR decofluor OR dectancyl OR dekacort OR delladec OR deltafluoren* OR dergramin OR deronil OR desacort OR 
desacortone OR desadrene OR desalark OR desameton* OR desigdron OR “dexa cortisyl” OR “dexa dabrosan” OR “dexa korti” OR “dexa scherosan” OR 
“dexa scherozon” OR “dexa scherozone” OR “dexa p” OR “dexacen 4” OR dexachel OR dexacort* OR dexadabroson OR dexadecadrol OR dexadrol OR 
dexagel OR dexagen OR dexahelvacort OR dexakorti OR dexalien OR dexalocal OR dexame OR dexamecortin OR dexameson* OR dexametason* OR 
dexamonozon OR dexan* OR dexapot OR dexascheroson OR dexascherozon* OR dexason* OR dexinoral OR dexionil OR dexmethsone OR dexona OR 
dexone OR “dexpak taperpak” OR dextelan OR dextrasone OR dexycu OR dezone OR dibasona OR dexamethasone OR esacortene OR exadion OR 
exadione OR firmalone OR “fluormethyl prednisolone” OR fluormethylprednisolon* OR fluormone OR fluorocort OR fluorodelta OR 
fluoromethylprednisolone OR fortecortin OR gammacorten* OR grosodexon* OR hexadecadiol OR hexadecadrol OR hexadiol OR hexadrol OR isnacort 
OR isopto* OR “lokalison f” OR loverine OR luxazone OR marvidione OR maxidex OR mediamethasone OR megacortin OR mephameson* OR 
metasolon* OR methazon* OR methylfluorprednisolone OR “metisone lafi” OR mexasone OR millicorten* OR mymethasone OR neoforderx OR neofordex 
OR nisomethasona OR novocort OR “oftan dexa” OR opticorten OR opticortinol OR oradexan OR oradexon* OR orgadrone OR ozurdex OR pidexon OR 
policort OR posurdex OR “predni f” OR “prednisolone f” OR prodexona OR prodexone OR sanamethasone OR santenson OR santeson OR sawasone OR 
solurex OR spoloven OR sterasone OR thilodexine OR tobradex OR triamcimetil OR vexamet OR visumetazone OR visumethazone))   
AND NOT KEY((Animals) AND NOT (Animals AND humans))  
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ClinicalTrials.gov   
Date Searched: 6/11/19 ; 5/13/20   
Number of Results:  35 ; 39  
search was re-run on May 13, 2020 and 4 additional records were found.   
  
in Expert search:   
(Antenatal corticosteroids) AND (preterm OR Small for Gestational Age OR birth weight)  
  
WHO ICTRP  
Date Searched: 6/11/19 ; unavailable  
Number of Results: 24  
From advanced search in search portal:   
Antenatal corticosteroid (in title)   
AND   
preterm OR small for gestational age OR birth weight (in condition)   
OR   
Antenatal corticosteroid (in intervention)  
recruitment status : ALL   
  
  
 




